Hepatocellular carcinoma to renal cell carcinoma metastasis: a rare phenomenon with diagnostic challenges

To the Editor: The coexistence of two or more synchronous or metachronous malignancies in the same patient is not uncommon.1 Tumor-to-tumor metastasis is, however, a rarer phenomenon.1,2 Probably, the first case reported in the literature was by Berent in 1902, in which squamous cell carcinoma of the jaw metastasized to renal cell carcinoma.3 Rabson et al found 50 reported cases of cancer-to-cancer metastasis in 1954.4 Petraki et al found 150 reported cases of tumor-to-tumor metastasis in 2003.1 We report a case of hepatocellular carcinoma metastasized into renal cell carcinoma.

A 70-year-old non-local woman presented with intermittent abdominal pain. Four months prior to current presentation the patient was diagnosed with hepatocellular carcinoma (HCC) in her home country and received one cycle of chemotherapy. The patient decided to travel abroad to complete her treatment in our hospital. Computed tomography showed a right hepatic lobe mass that measured 7.7 cm with chemoembolization material and a cirrhotic liver (Figure 1). The left kidney showed an upper pole nodule that measured 3.5 cm (Figure 1). The right kidney and adrenal glands were unremarkable. Alpha-fetoprotein (AFP) was high (66.3 IU/mL). Clinical and radiological differential diagnoses included incidental renal cell carcinoma or metastatic hepatocellular carcinoma of the left kidney nodule. The patient was scheduled for frozen section of the left renal nodule and subsequent segmental resection of the hepatic mass.

We received segmental resection of the left kidney nodule that grossly measured 3.6 cm and showed a yellow mass with areas of hemorrhage. A frozen section showed histologic features of clear cell carcinoma consistent with incidental renal cell carcinoma (RCC) of the left kidney. Subsequent permanent sections confirmed the frozen section diagnosis of low-grade conventional renal clear cell carcinoma. However, a smaller granular eosinophilic nodule (measuring 2.5 mm) was found within the renal cell carcinoma nodule (Figure 2). This nodule showed a highly pleomorphic eosinophilic neoplasm with focal trabecular and pseudoacinocr growth pattern lined by endothelial cells. High mitotic activity with atypical mitotic figures was present (Figure 2). Histologic differential diagnoses of the smaller
cosinophilic nodule included a focus of high-grade granular renal cell carcinoma, metastatic hepatocellular carcinoma or adrenal cortical cell carcinoma. Immunohistochemistry for CD10, HepPar-1, AFP and melan-A was done. The cosinophilic neoplastic cells of the small nodule were positive for HepPar-1 (Figure 3) and were negative for CD10, AFP and melan-A. The surrounding renal cell carcinoma cells were positive for CD10 (Figure 3) and negative for the remaining markers. We entertained the diagnosis of incidental low-grade renal cell carcinoma of the left kidney with metastatic HCC.

The liver mass was not resected because the patient developed severe life-threatening intraoperative bleeding and received several blood transfusions. The patient died two days after surgery because of uncontrollable hemorrhage. Because of social, ethical and religious restraints, postmortem examinations are not performed in our region, and therefore no autopsy study was carried out on the patient.

Tumor-to-tumor metastasis can occur in patients with synchronous or metachronous simultaneous primaries.\(^1,4\) This phenomenon is infrequent, but probably more common than previously reported.\(^1,2\) The receiving host neoplasm could be benign or malignant. The most common receiving malignancy is renal cell carcinoma.\(^1,2,4\) Other host neoplasms include sarcomas, meningiomas, thyroid neoplasms and pituitary adenomas.\(^1,2,4\) “The most common donor neoplasm is primary lung carcinoma followed by breast, prostate and thyroid carcinomas.\(^1,2,4\) Other metastatic donor malignancies reported included squamous cell carcinoma of the head and neck region, melanoma, and colonic and gastric carcinomas, but HCC has not been previously reported.\(^1,4\)

The definition of one primary malignancy metastasizing to another primary neoplasm within the same patient should be based on certain criteria. Campbell et al\(^5\) proposed a set of criteria for the diagnosis of tumor-to-tumor metastasis which include: 1) the existence of more than one primary tumor in the patient, 2) the recipient tumor must be a true neoplasm, 3) the donor tumor must be a true metastasis (direct contiguous spreading or collision tumor is not acceptable), and 4) lymphatic metastasis should be excluded. The reason why RCC was the most common host malignancy is unclear. Several theories have attempted to explain why non-metastasizing early renal cell carcinoma is the favorite host tumor in cancer-to-cancer metastasis.\(^1,2\) These mechanical and biochemical factors include: 1) the kidneys are vascular organs with abundant blood supply, 2) RCC is a very vascular neoplasm, 3) RCC provides a lipid and glycogen rich environment for tumor growth, 4) angiogenic or hormonal secretion by RCC cells, and 5) early low-grade RCC provides an aerobic oxygen-rich metabolic environment suitable for tumor growth. These hypotheses need validation by more probing studies that may shed light into the behavior and underlying pathogenesis of metastasizing cancers.

It is sometimes difficult to distinguish between renal cell carcinoma and HCC, particularly clear cell types. Clues to HCC might include the presence of focal trabecular and pseudoglandular growth pattern.\(^6,7\) The presence of bile pigments and Mallory bodies are helpful, but they are not always present particularly in high grade HCC.\(^6,7\) Immunohistochemistry with a small panel of HepPar-1 and CD10 can help.\(^6,7\) HepPar-1 is the most specific marker for hepatic differentiation.\(^6,7\) It can be patchy and variable sometimes, but shows characteristic granular cytoplasmic staining.\(^6,7\) HepPar-1 is almost always negative in RCC.\(^6,7\) CD10 is a good marker for RCC, but not specific. It can be positive in HCC, but usually shows a canalicular pattern in the trabecular areas as opposed to the brisk membrane stain-
CD123 monoclonal antibody in myelodysplastic syndrome

To the Editor: CD123 monoclonal antibody is an IL3Rα antireceptor useful in the diagnosis of hairy cell leukemia.\textsuperscript{1} It is widely used to recognize minimal residual disease (MRD) in treated acute myeloid leukemia (AML). We studied 20 patients with a diagnosis of myelodysplastic syndrome (MDS). The most prominent clinical sign was leukopenia with variable lymphocytosis, and disease evolution of more than a year. Patient ages ranged between 32 to 81 years, and included 11 women and 9 men. Laboratory bone marrow findings were consistent with hypercellular and heteromorphic cytology with erythroid dysplasia and the presence of Pelger-Huet anomaly, with increased intermediary forms, immature myeloid series and macroplatelets. Serum iron and ferritin were measured and one marrow iron and biopsy were obtained. Flow cytometry monoclonal antibodies used included CD34 + CD123, CD38 + CD123, CD34 + CD117, CD34 + CD38, CD123, and p53 and Bcl2. These monoclonal combinations were studied to determine the presence of leukemic stem cells (LSC). The analysis showed evidence of CD123 in 12 patients, with more than 20% (range, 22%-66%). In the remaining 8 patients, CD123 was less than 20% (range, 6%-16%). The CD34 + CD117 combination findings corresponded with 16%-56%. The patient samples were also marked with CD38, with a presence of 39%-82%, indicating cellular activation. When compared with CD34 + CD123, the range was 20%-95%. Taking into account total positivity, all our patients had an increased presence of CD123, in addition to CD34 and CD117. Eleven (n=11) patients presented with alterations in p53, and 14 had the presence BCL2 oncogene. Patients with more than 20% CD123 were treated with anti-methylation drugs. Our conclusions indicate that the use of CD123 with other immaturity markers corresponds with MDS and relates to the presence of LSC. The use of this marker may help in early identification and treatment of cases with higher potential for leukemic transformation. Limited but similar findings have been reported about the value of CD123, under comparable conditions.\textsuperscript{2}

Luigi De Salvo, Rodolfo Salas, Dalila De Salvo, Weir Jesús Medina, Anamaria Nunez, Zaida Plumacher, Olga Fernandez, Mariela Acosta, Mirian Duerto, Luis Paz, Dalida Salas, Alba Fuenmayor

From the Institute Hematology Occidente, Maracaibo, Venezuela

Correspondence: Luigi De Salvo, MD
Flow Cytometry Lab Chief
Inst Hematol Occidente
Final Av 20, Lado Castillo-Plaza
Maracaibo, 4001 Venezuela
T: +58-424-6088191
F: +58-261-7831754
luigidesalvom@cantv.net

DOI: 10.5144/1658-3876.2011.105

REFERENCES


Badr AbdullGaffar,\textsuperscript{a} Lakshmi G. Raman,\textsuperscript{b} Ahmed ElBarkouki\textsuperscript{b}

From the ‘Dubai Hospital and Al-Baraha Hospital, Dubai, United Arab Emirates

Correspondence: Badr AbdullGaffar, MD Department of Histopathology, Dubai Hospital, AlKhalajej Road, Community 354, Dubai 7272 United Arab Emirates
T: +97143943565
F: +97143446972
badr.agaffar@gmail.com

DOI: 10.5144/1658-3876.2011.105

REFERENCES

4. Campbell LV, Gilbert E, Chamberlain CR, Watne AL. Measurement of DC123, IL-3 receptor α chain, eliminates human hematopoietic stem cells. Cell Stem Cell 2010; 6: 82%, indicating cellular activation. When compared with CD34 + CD123, the range was 20%-95%. Taking into account total positivity, all our patients had an increased presence of CD123, in addition to CD34 and CD117. Eleven (n=11) patients presented with alterations in p53, and 14 had the presence BCL2 oncogene. Patients with more than 20% CD123 were treated with anti-methylation drugs. Our conclusions indicate that the use of CD123 with other immaturity markers corresponds with MDS and relates to the presence of LSC. The use of this marker may help in early identification and treatment of cases with higher potential for leukemic transformation. Limited but similar findings have been reported about the value of CD123, under comparable conditions.\textsuperscript{2}

Luigi De Salvo, Rodolfo Salas, Dalila De Salvo, Weir Jesús Medina, Anamaria Nunez, Zaida Plumacher, Olga Fernandez, Mariela Acosta, Mirian Duerto, Luis Paz, Dalida Salas, Alba Fuenmayor

From the Institute Hematology Occidente, Maracaibo, Venezuela

Correspondence: Luigi De Salvo, MD
Flow Cytometry Lab Chief
Inst Hematol Occidente
Final Av 20, Lado Castillo-Plaza
Maracaibo, 4001 Venezuela
T: +58-424-6088191
F: +58-261-7831754
luigidesalvom@cantv.net

DOI: 10.5144/1658-3876.2011.105

REFERENCES